查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1495992

全球自动注射器市场：2024-2029 年预测

Global Auto Injector Market - Forecasts from 2024 to 2029
出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 134 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

2022年全球自动注射器市值为691.71亿美元，预计复合年增长率为19.39%，到2029年市场规模将达到2391.45亿美元。

自动注射器是一种带有弹簧针头的注射器，预先装有一定剂量的药物或药物。与传统注射器相比，自动注射器提供的便利性和易用性增加了对自动注射器的需求。它们受到广泛的青睐，因为与传统注射器相比，它们可以减少患者的焦虑和恐慌。

慢性疾病患者数量的增加正在推动全球自动注射器市场的成长。与传统注射器相比，自动注射器普及和接受的主要因素之一是自动注射器减少了患者的焦虑。此外，由于自动注射器预先装有药物，因此它提高了自动注射器对医疗专业人员的有效性和便利性。自动注射器报告的错误率低于传统注射器。

主要市场参与者对医疗药物注射研究和技术开发的大量投资也促进了自动注射器市场的成长。此外，居家医疗诊断和医疗保健的不断增长趋势也增加了对全球自动注射器市场的需求。由于过敏反应病例的增加，自动注射器广泛用于自行注射肾上腺素以预防过敏反应，这也推动了自动注射器市场的成长。

市场驱动因素：

  • 预计慢性疾病患者数量的增加将推动自动注射器市场的发展。

慢性疾病患者数量的增加是推动全球自动注射器市场成长的主要因素之一。过敏反应病例的增加也推动了自动注射器市场的成长，因为治疗过敏反应的药物通常是在自动注射器的帮助下自行注射给患者。

根据世界过敏组织 (WAO) 全球情势，成人过敏反应病例的比例高于儿童。患有过敏反应的成年人和老年人主要寻求自动注射器的帮助来服用肾上腺素等药物。根据 PAHO（泛美卫生组织）的数据，约 2% 的美国人口面临过敏反应的影响。

与传统注射器相比，居家医疗文明病等的成长趋势也推动了自动注射器的市场成长。自动注射器提供的自我管理优势和给药有效性正在推动全球自动注射器的市场价值。

  • 企业投资的增加预计将推动市场成长。

主要市场参与者对注射器和自动注射器的大量投资为全球自动注射器市场的成长带来了潜力。药品管理管理领域的研究和发展正在技术上加强和推动自动注射器领域的发展。

政府对医疗领域研发的支持也带动了自动注射器市场的成长。 Amgen 和 Antares Pharma 等公司的大量投资和参与也导致了自动注射器领域的整合和发展。

北美地区所占份额最大。

从地区来看，北美地区在全球自动注射器市场中占据主要份额。自动注射器广泛使用的过敏反应和关节炎等疾病病例的增加正在推动北美地区自动注射器市场的成长。亚太地区自动注射器市场持续成长。

由于糖尿病、类风湿性关节炎和多发性硬化症等慢性疾病的高发，北美，特别是美国和加拿大，成为自动注射器的主要市场。该地区先进的医疗基础设施、技术进步和法规环境有助于这些设备的快速普及。病人偏好、教育和经济因素也影响自动注射器的需求。

该地区强劲的经济实力可能会导致自动注射器等先进医疗设备的医疗保健支出增加。总部位于北美或在北美拥有强大影响力的大型製药和医疗设备公司的存在可能会进一步提高该地区的市场占有率。

主要进展：

  • 2023 年 5 月 - SHL Medical 和 MoonLake Immuntherapeutics 共同开发了 MoonLake 奈米抗体 sonelokimab 的自动注射器。选择 Molly 自动注射器技术这个模组化平台是为了减少初始投资并缩短开发时间。 SHL Medical 将提供设备开发专业知识、组装指导和製造能力，以支援您的 sonelokimab 配方开发计划。 MoonLake Immuntherapeutics技术长Oliver Daltrop 对此合作感到兴奋。
  • 2022 年 10 月 - BioCorp 和 BD 合作，利用连网型技术来追踪自我管理药物治疗（包括生技药品）的依从性。 BioCorp 的 Injay 技术使用近场通讯，与用于预充式註射器的 BD UltraSafe Plus(TM) 被动护针器整合。这种整合旨在提高注射药物的依从性和结果。
  • 2022 年 5 月 - Jabiru Healthcare 宣布推出 Qfinity(TM) 自动注射器平台。该平台是一种可重复使用的模组化解决方案，可支援皮下药物的自我给药，且成本低于市场上的替代品。该平台旨在让患者自行注射各种注射剂，包括大容量、高黏度药物，每单位注射量超过 100 次。 Qfinity+ 提供以患者为中心的外形尺寸，也解决了医疗废弃物的挑战，因为一次性塑胶注射器在医疗塑胶废弃物中所占比例最高。
  • 2022 年 5 月 - Stevanato Group 与 Owen Mumford Ltd. 合作，开始製造 Aidaptus® 自动注射器平台。透过此次合作，斯蒂瓦那托集团将模製组件、提供最终和分装设备，并提供市场领先的预填充式注射器。组装将在 Stevanato Group 和 Owen Mumford 的英国自动化组装中心进行。此次合作将简化设备生产并最大限度地发挥 Aidaptus® 平台的价值，这是一款与 1mL 和 2.25mL预填充玻璃注射器相容的多功能两步式一次性自动注射器。

目录

第一章简介

  • 市场概况
  • 市场定义
  • 调查范围
  • 市场区隔
  • 货币
  • 先决条件
  • 基准年和预测年时间表
  • 相关利益者的主要利益

第二章调查方法

  • 研究设计
  • 调查过程

第三章执行摘要

  • 主要发现

第四章市场动态

  • 市场驱动因素
  • 市场限制因素
  • 波特五力分析
  • 产业价值链分析
  • 分析师观点

第五章全球自动注射器市场：按类型

  • 介绍
  • 一次性自动注射器
    • 市场机会和趋势
    • 成长前景
    • 地域获利能力
  • 可重复使用的自动注射器
    • 市场机会和趋势
    • 成长前景
    • 地域获利能力

第六章全球自动注射器市场：依应用分类

  • 介绍
  • 类风湿性关节炎
    • 市场机会和趋势
    • 成长前景
    • 地域获利能力
  • 过敏反应
    • 市场机会和趋势
    • 成长前景
    • 地域获利能力
  • 多发性硬化症
    • 市场机会和趋势
    • 成长前景
    • 地域获利能力
  • 其他的
    • 市场机会和趋势
    • 成长前景
    • 地域获利能力

第七章全球自动注射器市场：依最终使用者分类

  • 介绍
  • 居家照护环境
    • 市场机会和趋势
    • 成长前景
    • 地域获利能力
  • 医院/诊所
    • 市场机会和趋势
    • 成长前景
    • 地域获利能力

第八章全球自动注射器市场：按地区

  • 介绍
  • 北美洲
    • 按类型
    • 按用途
    • 按最终用户
    • 按国家/地区
  • 南美洲
    • 按类型
    • 按用途
    • 按最终用户
    • 按国家/地区
  • 欧洲
    • 按类型
    • 按用途
    • 按最终用户
    • 按国家/地区
  • 中东/非洲
    • 按类型
    • 按用途
    • 按最终用户
    • 按国家/地区
  • 亚太地区
    • 按类型
    • 按用途
    • 按最终用户
    • 按国家/地区

第九章竞争环境及分析

  • 主要企业及策略分析
  • 市场占有率分析
  • 合併、收购、协议和合作
  • 竞争对手仪表板

第十章 公司简介

  • Amgen
  • Antares Pharma
  • Becton Dickinson and Company
  • Eli Lilly and Company
  • Johnson and Johnson
  • Mylan NV
  • Novartis AG
  • SHL Medical
  • Teva Pharmaceutical Industries Ltd
  • Ypsomed AG
简介目录
Product Code: KSI061611775

The global auto-injector market is evaluated at US$69.171 billion for the year 2022 and is projected to grow at a CAGR of 19.39% to reach a market size of US$239.145 billion by the year 2029.

Auto-injectors are syringes accompanied by a spring-charged needle with a pre-charged dosage of drugs or medicine. The convenience and user-friendliness offered by auto-injectors are increasing the demand for auto-injectors over conventional syringes. They are widely preferred over conventional syringes as they reduce anxiety and panic in patients compared to conventional syringes.

The increasing cases of chronic diseases have boosted the global auto-injector market growth. One of the major factors increasing the popularity and acceptability of auto-injectors over conventional syringes is the reduced anxiety caused by auto-injectors in patients. The pre-charged dosage of drugs in auto-injectors also increases the effectiveness and convenience of auto-injectors for medical practitioners. The percentage of errors reported in auto-injectors is lower than that of conventional syringes.

The significant investments in research and technological developments in medical drug injection by major market players are also contributing to the auto-injector market growth. The rising trend of home-based medical diagnosis and medical care also increases the demand for auto-injectors in the global market. The wide use of auto-injectors for the self-injection of epinephrine to prevent anaphylaxis is also boosting the market growth of auto-injectors as cases of anaphylaxis are increasing.

Market Drivers:

  • Rising cases of chronic diseases are anticipated to propel the global auto injector market.

The rising cases of chronic diseases are one of the major factors driving the global auto-injectors market growth. The increasing rate of anaphylaxis cases is also pushing the market growth of auto-injectors, as the drug for the treatment of anaphylaxis is usually self-administered to patients with the help of auto-injectors.

According to the global overview of WAO (World Allergic Organisation), the percentage of anaphylaxis cases is mostly reported in adults compared to children. Adults or older people affected by anaphylaxis mainly seek the support of self-administered auto-injectors for the dosage intake of drugs like epinephrine. According to PAHO (Pan American Health Organisation), about 2% of the total American population is facing the effects of anaphylaxis.

The rising trend of home-based medical care for lifestyle diseases and others is also fuelling the market growth of auto-injectors compared to conventional syringes. The benefits offered by auto-injectors in self-administration and effectiveness in dosage quantity are pushing the market value of auto-injectors globally.

  • Rising investment in companies is expected to surge the market growth.

The significant investments offered by major market players in injectors and self-injectors are giving potential to the global market growth of auto-injectors. The research and developments taking place in drug dosage administration are technically enhancing and developing the sector of auto-injectors.

The support offered by the government in research and development in the medical field is also resulting in the auto-injector market growth. The large investments and involvement of companies like Amgen and Antares Pharma are also leading to enhancement and development in the field of autoinjectors.

The North American region accounted for the largest share.

Geographically, the North American region accounts for the major market share in the global auto-injector market. The increasing cases of anaphylaxis, arthritis, and other diseases in which auto-injectors are widely used are fuelling the market growth of auto-injectors in the North American region. The Asia-Pacific region follows the market growth of the auto-injectors.

North America, particularly the United States and Canada, is a major market for auto-injectors due to its high prevalence of chronic diseases like diabetes, rheumatoid arthritis, and multiple sclerosis. The region's advanced healthcare infrastructure, technological advancements, and regulatory environment contribute to the rapid adoption of these devices. Patient preferences and education, along with economic factors, also influence the demand for auto-injectors.

The region's strong economic strength may lead to higher healthcare spending on advanced medical devices like auto-injectors. The presence of major pharmaceutical and medical device companies headquartered or with a strong presence in North America can further boost the region's market share.

Key Developments:

  • May 2023- SHL Medical and MoonLake Immunotherapeutics collaborated to create an autoinjector for MoonLake's Nanobody sonelokimab, a drug designed to target inflammation sites and penetrate inflamed tissues and joints. The Molly autoinjector technology, a modular platform, was used to reduce initial investments and expedite development timelines. SHL Medical will provide device development expertise, assembly guidance, and production competencies to support the sonelokimab drug-device project. MoonLake Immunotherapeutics Chief Technical Officer Oliver Daltrop is excited about the collaboration.
  • October 2022- Biocorp and BD partnered to use connected technology to track adherence for self-administered drug therapies, including biologics. Biocorp's Injay technology, which uses Near Field Communication integrated with BD UltraSafe Plus(TM) Passive Needle Guard for prefillable syringes. The integration aims to improve adherence and outcomes of injectable drugs. The global connected drug delivery market is expected to grow at double-digit rates over the next decade due to shifts from acute care to home care and increased self-administered therapies.
  • May 2022- Jabil Healthcare introduced the Qfinity(TM) autoinjector platform, a reusable and modular solution for subcutaneous drug self-administration at a lower cost than market alternatives. The platform can handle over 100 injections per device and is designed to help patients self-administer various injectables, including larger volume, higher viscosity medicines. It offers a patient-centric form factor and addresses the challenge of medical waste, as plastic disposable syringes generate the highest percentage of medical-grade plastic waste. The Qfinity+ autoinjector also offers a connected version for remote monitoring.
  • May 2022- Stevanato Group partnered with Owen Mumford Ltd. to manufacture the Aidaptus(R) auto-injector platform, offering pharmaceutical customers a full range of capabilities. The partnership involved Stevanato Group molding components, providing final and sub-assembly equipment, and offering market-leading pre-filled syringes. Assembly carried out by both Stevanato Group and Owen Mumford at their UK automated assembly center. The collaboration aims to streamline device production and deliver the full value of the Aidaptus(R) platform, which is a versatile 2-step, single-use auto-injector that accommodates both 1mL and 2.25 mL prefilled glass syringes.

Market Segmentation:

By Type

  • Disposable autoinjectors
  • Reusable autoinjectors

By Application

  • Rheumatoid Arthritis
  • Anaphylaxis
  • Multiple sclerosis
  • Others

By End-user

  • Homecare settings
  • Hospitals & Clinics

By Geography

  • North America
  • USA
  • Canada
  • Mexico
  • South America
  • Brazil
  • Argentina
  • Others
  • Europe
  • Germany
  • France
  • UK
  • Others
  • Middle East and Africa
  • Saudi Arabia
  • UAE
  • Others
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Taiwan
  • Thailand
  • Indonesia
  • Others

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. Market Overview
  • 1.2. Market Definition
  • 1.3. Scope of the Study
  • 1.4. Market Segmentation
  • 1.5. Currency
  • 1.6. Assumptions
  • 1.7. Base and Forecast Years Timeline
  • 1.8. Key Benefits to the Stakeholder

2. RESEARCH METHODOLOGY

  • 2.1. Research Design
  • 2.2. Research Processes

3. EXECUTIVE SUMMARY

  • 3.1. Key Findings

4. MARKET DYNAMICS

  • 4.1. Market Drivers
  • 4.2. Market Restraints
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers
    • 4.3.2. Bargaining Power of Buyers
    • 4.3.3. Threat of New Entrants
    • 4.3.4. Threat of Substitutes
    • 4.3.5. Competitive Rivalry in the Industry
  • 4.4. Industry Value Chain Analysis
  • 4.5. Analyst View

5. GLOBAL AUTO INJECTOR MARKET BY TYPE

  • 5.1. Introduction
  • 5.2. Disposable autoinjectors
    • 5.2.1. Market Opportunities and Trends
    • 5.2.2. Growth Prospects
    • 5.2.3. Geographic Lucrativeness
  • 5.3. Reusable autoinjectors
    • 5.3.1. Market Opportunities and Trends
    • 5.3.2. Growth Prospects
    • 5.3.3. Geographic Lucrativeness

6. GLOBAL AUTO INJECTOR MARKET BY APPLICATION

  • 6.1. Introduction
  • 6.2. Rheumatoid Arthritis
    • 6.2.1. Market Opportunities and Trends
    • 6.2.2. Growth Prospects
    • 6.2.3. Geographic Lucrativeness
  • 6.3. Anaphylaxis
    • 6.3.1. Market Opportunities and Trends
    • 6.3.2. Growth Prospects
    • 6.3.3. Geographic Lucrativeness
  • 6.4. Multiple sclerosis
    • 6.4.1. Market Opportunities and Trends
    • 6.4.2. Growth Prospects
    • 6.4.3. Geographic Lucrativeness
  • 6.5. Others
    • 6.5.1. Market Opportunities and Trends
    • 6.5.2. Growth Prospects
    • 6.5.3. Geographic Lucrativeness

7. GLOBAL AUTO INJECTOR MARKET BY END-USER

  • 7.1. Introduction
  • 7.2. Homecare settings
    • 7.2.1. Market Opportunities and Trends
    • 7.2.2. Growth Prospects
    • 7.2.3. Geographic Lucrativeness
  • 7.3. Hospitals & Clinics
    • 7.3.1. Market Opportunities and Trends
    • 7.3.2. Growth Prospects
    • 7.3.3. Geographic Lucrativeness

8. GLOBAL AUTO INJECTOR MARKET BY GEOGRAPHY

  • 8.1. Introduction
  • 8.2. North America
    • 8.2.1. By Type
    • 8.2.2. By Application
    • 8.2.3. By End-User
    • 8.2.4. By Country
      • 8.2.4.1. USA
        • 8.2.4.1.1. Market Opportunities and Trends
        • 8.2.4.1.2. Growth Prospects
      • 8.2.4.2. Canada
        • 8.2.4.2.1. Market Opportunities and Trends
        • 8.2.4.2.2. Growth Prospects
      • 8.2.4.3. Mexico
        • 8.2.4.3.1. Market Opportunities and Trends
        • 8.2.4.3.2. Growth Prospects
  • 8.3. South America
    • 8.3.1. By Type
    • 8.3.2. By Application
    • 8.3.3. By End-User
    • 8.3.4. By Country
      • 8.3.4.1. Brazil
        • 8.3.4.1.1. Market Opportunities and Trends
        • 8.3.4.1.2. Growth Prospects
      • 8.3.4.2. Argentina
        • 8.3.4.2.1. Market Opportunities and Trends
        • 8.3.4.2.2. Growth Prospects
      • 8.3.4.3. Others
        • 8.3.4.3.1. Market Opportunities and Trends
        • 8.3.4.3.2. Growth Prospects
  • 8.4. Europe
    • 8.4.1. By Type
    • 8.4.2. By Application
    • 8.4.3. By End-User
    • 8.4.4. By Country
      • 8.4.4.1. Germany
        • 8.4.4.1.1. Market Opportunities and Trends
        • 8.4.4.1.2. Growth Prospects
      • 8.4.4.2. France
        • 8.4.4.2.1. Market Opportunities and Trends
        • 8.4.4.2.2. Growth Prospects
      • 8.4.4.3. UK
        • 8.4.4.3.1. Market Opportunities and Trends
        • 8.4.4.3.2. Growth Prospects
      • 8.4.4.4. Others
        • 8.4.4.4.1. Market Opportunities and Trends
        • 8.4.4.4.2. Growth Prospects
  • 8.5. Middle East and Africa
    • 8.5.1. By Type
    • 8.5.2. By Application
    • 8.5.3. By End-User
    • 8.5.4. By Country
      • 8.5.4.1. Saudi Arabia
        • 8.5.4.1.1. Market Opportunities and Trends
        • 8.5.4.1.2. Growth Prospects
      • 8.5.4.2. UAE
        • 8.5.4.2.1. Market Opportunities and Trends
        • 8.5.4.2.2. Growth Prospects
      • 8.5.4.3. Others
        • 8.5.4.3.1. Market Opportunities and Trends
        • 8.5.4.3.2. Growth Prospects
  • 8.6. Asia Pacific
    • 8.6.1. By Type
    • 8.6.2. By Application
    • 8.6.3. By End-User
    • 8.6.4. By Country
      • 8.6.4.1. China
        • 8.6.4.1.1. Market Opportunities and Trends
        • 8.6.4.1.2. Growth Prospects
      • 8.6.4.2. India
        • 8.6.4.2.1. Market Opportunities and Trends
        • 8.6.4.2.2. Growth Prospects
      • 8.6.4.3. Japan
        • 8.6.4.3.1. Market Opportunities and Trends
        • 8.6.4.3.2. Growth Prospects
      • 8.6.4.4. South Korea
        • 8.6.4.4.1. Market Opportunities and Trends
        • 8.6.4.4.2. Growth Prospects
      • 8.6.4.5. Taiwan
        • 8.6.4.5.1. Market Opportunities and Trends
        • 8.6.4.5.2. Growth Prospects
      • 8.6.4.6. Thailand
        • 8.6.4.6.1. Market Opportunities and Trends
        • 8.6.4.6.2. Growth Prospects
      • 8.6.4.7. Indonesia
        • 8.6.4.7.1. Market Opportunities and Trends
        • 8.6.4.7.2. Growth Prospects
      • 8.6.4.8. Others
        • 8.6.4.8.1. Market Opportunities and Trends
        • 8.6.4.8.2. Growth Prospects

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

  • 9.1. Major Players and Strategy Analysis
  • 9.2. Market Share Analysis
  • 9.3. Mergers, Acquisitions, Agreements, and Collaborations
  • 9.4. Competitive Dashboard

10. COMPANY PROFILES

  • 10.1. Amgen
  • 10.2. Antares Pharma
  • 10.3. Becton Dickinson and Company
  • 10.4. Eli Lilly and Company
  • 10.5. Johnson and Johnson
  • 10.6. Mylan N.V.
  • 10.7. Novartis AG
  • 10.8. SHL Medical
  • 10.9. Teva Pharmaceutical Industries Ltd
  • 10.10. Ypsomed AG